Kornimate/medical-research-clean huggingface dataset:
accelerated body diffusion-weighted mri using artificial intelligence

Conditions: Cancer

Summary: whole-body diffusion-weighted mri (wbdwi) is a non-invasive tool used for staging and response evaluation in oncologic practice and is at the core of emerging response criteria in advanced prostate and breast cancers. wbdwi is a sensitive tool that radiologists can use to review the extent of disease and is achieved using a series of sequential imaging stations from the head to the mid-thigh. wbdwi accounts for more than 50% of the acquisition time of conventional whole-body mri studies with a 1-hour duration. despite national and international guidance for using whole-body mri, a recent uk survey indicated that only 27% of uk radiology departments were offering a whole-body mri service with a lack of scanner availability cited by 50% of respondents as the main challenge to service delivery. in the context of the ever-increasing capacity pressures on mri departments, reducing acquisition times would facilitate the wider adoption of clinical wbdwi, reduce costs, and improve the patient experience. dwi is also embedded into consensus mri protocols across almost all tumour types including primary prostate and breast cancers, metastatic liver disease, gynaecological cancers \& gi cancers, where acquisition time savings could also be beneficial. the investigators have previously published accelerated dwi with deep learning based denoising filters (quickdwi), which can provide up to 50% reduction in whole-body mri acquisition times. the goal of the deep-learning algorithm is to remove the noise in these subsampled images, producing an image with acceptable clinical quality. the aim of this investigation is to extend this work by testing quickdwi within a larger retrospective data cohort, incorporating other cancers such as disease of the abdomen and pelvis, primary prostate cancer, liver metastases, and pancreatic cancer.


Eligibility criteria:
1. patients who have received one of the following mri examinations (scan type shown in parentheses): * multiple myeloma (whole-body) * metastatic prostate cancer (whole-body) * metastatic breast cancer (whole-body) * liver metastases (stacked abdomen/pelvis) * pancreatic cancer (stacked abdomen/pelvis) * gynaecological cancers (stacked abdomen/pelvis) * gastrointestinal cancers (stacked abdomen/pelvis) * primary prostate cancers (multiparametric prostate exam) 2. patients who have received one of the above-mentioned scan types using a modified clinical multi-direction diffusion-weighted (mddw) mri protocol as part of standard of care. exclusion criteria: * no exclusion criteria as this is a retrospective data study only.
scoliosis surgery using the pass® lp system

Conditions: Idiopathic Scoliosis

Summary: the purpose of this study is to find out the outcomes of using the pass lp system to correct idiopathic scoliosis. this system is a unique set of spinal instrumentation used to surgically correct the rotation and deformity of the spine that is caused by scoliosis. also, this study wants to find out the effects this system has on the physical appearance and quality of life for patients with scoliosis.

the aim of this study is to evaluate the clinical, functional and radiographic outcomes following the reduction of idiopathic scoliosis. the following will be evaluated 1. the 3d correction of scoliosis: * reduction of scoliosis in the coronal plane (cobb angles) * correction in the sagittal plane (kyphotic and lordotic angles) * correction of the axial vertebral rotation in the transverse plane 2. the functional and aesthetic outcomes

Eligibility criteria:
inclusion criteria: * idiopathic scoliosis requiring posterior spinal instrumentation and fusion * male and female exclusion criteria: * neuromuscular or degenerative scoliosis * spinal cord abnormalities with any neurologic symptoms or signs * spinal cord lesions requiring neurosurgical interventions, such as hydromyelia requiring arnold chiari decompression * primary muscle diseases, such as muscular dystrophy * neurologic diseases (e.g. charcot-marie tooth, guillain-barre syndrome, cerebral palsy, or spina bifida, neurofibroma) * primary abnormalities of bones (e.g. osteogenesis imperfecta) * congenital scoliosis * scoliosis requiring anterior release * previous spinal surgery * patient who is unable to complete a self-administered patient questionnaire

Keywords: scoliosis
effect of bosentan on endothelial function in patients with type 2 diabetes

Conditions: Type 2 Diabetes Mellitus

Summary: the purpose of the study is to investigate if oral treatment with bosentan improves endothelium-dependent vasodilatation in patients with type 2 diabetes and microangiopathy.


Eligibility criteria:
inclusion criteria: 1. diabetes mellitus type 2 of \>2 years duration 2. albuminuria exclusion criteria: 1. age \>80 years 2. myocardial infarction/unstable angina within three months prior to randomisation 3. decompensated congestive heart failure or functional class 3 and 4. 4. changes in dosage of any vasodilator drugs during the preceding six weeks 5. women of fertile age. 6. impaired hepatic function (2 times upper normal limit of aminotransferases asat and alat) 7. ongoing treatment with glibenclamide, cyclosporin or warfarin 8. any concomitant disease or condition that may interfere with the possibility for the patient to comply with or complete the study protocol 9. participant in an ongoing study 10. unwillingness to participate following oral and written information
use of apremilast in patients who are dissatisfied with stable maintenance topical therapy

Conditions: Plaque Psoriasis

Summary: sixteen week open label study of apremilast in combination with topical steroids with a four week safety follow up visit.

this is an open label, 16 week study of apremilast in combination with topical corticosteroids (tcs). twenty qualified subjects will be enrolled. visits will consist of baseline, 8 week, 16 week and a 20 week safety follow up after 4 weeks off treatment. subjects will dose with apremilast as per label. topical corticosteroids (tcs) will be used for up to week 4 as per label and then will be used on an as needed basis until week 16. assessments will include static physicians global assessment (spga), psoriasis area severity index (pasi), psoriatic body surface area (bsa), dermatology life quality index (dlqi),assessment of pruritus, patient satisfaction questionnaire. and patient global assessment (ptga)

Eligibility criteria:
inclusion criteria: * subjects must be in general good health as judged by investigator * female of childbearing potential (fcbp) must have a negative pregnancy test at screening and baseline. * fcbp must use an approved method of contraception as outlined in the protocol. * male subjects who engage in activity in which conception is possible must use barrier contraception as defined in the protocol. * 18 years of age or older * understand and voluntarily sign the informed consent * able to adhere to study visit schedule * moderate plaque type psoriasis as define by a a pga of 3 * bsa 0f 5-10% or a dlqi score of 7 or more * history of uncontrolled plaque psoriasis after either stable dose of high potency topical steroids for 2 weeks or mid-potency steroids for 4 weeks within the last 6 months exclusion criteria: * any clinically significant disease as determined by the investigator or major disease that is currently uncontrolled * any condition, including the presence of laboratory abnormalities, which would place the subject at unacceptable risk * prior history of suicide attempt at any time in the subject's lifetime prior to screening or randomization, or major psychiatric illness requiring hospitalization within the last 3 years * pregnant or breastfeeding, fcbp who are not willing to use acceptable birth control methods. * active substance abuse or a history of substance abuse within 6 months prior to screening. * malignancy or history of malignancy except fo treated (cured) basal cell or or squamous cell in situ skin carcinomas, treated (cured) cervical intraepithelial neoplasia or carcinoma in situ of the cervix with no evidence of recurrence within the previous 5 years * has not completed the prescribed washout for restricted treatments * known or suspected allergy to investigational product * other types of psoriasis * prior history of depression * prior use of apremilast
pillcam colon capsule endoscopy for ulcerative colitis

Conditions: Ulcerative Colitis

Summary: pillcam colon capsule (pcc) endoscopy is a novel strategy tool to inspect colon mucosa. the aim of the present study is to evaluate if pcc endoscopy is able to precisely investigate patients with ulcerative colitis and reach high consistency to conventional colonoscopy.

symptomatic patients with confirmed ulcerative colitis (uc) were enrolled in this prospective single-center study. no sooner had patients gone through pillcam colon capsule (pcc) endoscopy solution than they got conventional colonoscopy which is recognized as the "gold standard" examination technique. the extent of mucosal damage and inflammatory lesions during both modalities were recorded for comparison. in addition, the regimen of bowel preparation, completion rate, colonic cleanliness, compliance or adverse events were analyzed.

Eligibility criteria:
inclusion criteria: * adult patients (aged 18-70) * ulcerative colitis history * suffering from symptoms such as hematochezia, diarrhea or abdominal pain exclusion criteria: * patients with a high risk for capsule retention (such as intestinal diverticula, acute abdominal pain without regular defecation indicating intestinal obstruction or a history of abdominal operation or intestinal reconstructed operation), * patients allergic to sodium phosphate or polyethylene glycol (peg) solution, * patients with a history of crohn's disease * patients with serious systematic diseases such as congestive heart failure, renal failure or severe liver disease.

Keywords: pillcam colon capsule endoscopy conventional colonoscopy ulcerative colitis endoscopic manifestation colonoscopy
non-invasive and invasive assessment of coronary artery disease

Conditions: Coronary Artery Disease

Summary: the purpose of the study is to assess the diagnostic accuracy of a combined use of non-invasive coronary angiography with multi-slice computed tomography (msct) and stress cardiac magnetic resonance (cmr) imaging in patients with obstructive lesions on msct and with low to intermediate pre-test likelihood of coronary artery disease (cad) as compared to invasive coronary angiography (cag) and fractional flow reserve (ffr) measurements.


Eligibility criteria:
inclusion criteria: 1. patients with stable angina pectoris with low to intermediate pre-test likelihood of cad; 2. no previous history of cad; 3. obstructive stenosis (≥50% luminal narrowing) on msct coronary angiography; 4.informed consent. exclusion criteria: 1. patients with a previous history of cad; 2. patients with contraindications for msct: a.cardiac rhythms other than sinus rhythm, b.pregnancy, c.allergy for contrast medium, d.renal failure (estimated glomerular filtration rate (egfr) \ 75 bpm plus contra-indications for beta-blockade, f. weight \>100 kilograms; 3. contraindications for cardiac magnetic resonance (cmr) imaging: a.mr-incompatible implants, b. claustrophobia, c. contraindications for adenosine: i. known or suspected hypersensitivity to adenosine, ii. known or suspected bronchoconstrictive or bronchospastic disease, iii. 2nd or 3rd degree atrioventricular (av) block, iv. sinus bradycardia (heart rate \< 45 bpm), v. systemic arterial hypotension (\<90 mmhg). d. contraindications for gadolinium: i. renal failure (estimated egfr \<30 ml/min); 4. no informed consent.

Keywords: coronary artery disease computed tomography cardiac magnetic resonance fractional flow reserve
the effects of three different ultrasound-guided nerve blocks in vats

Conditions: Thoracic Anesthesia; Nerve Block; Pain, Acute

Summary: ultrasound-guided mid-point transverse process to pleura block, erector spinae plane block and paravertebral block are three different methods of nerve block, used for relieving postoperative pain in thoracic anesthesia. this study is to compare them on block effects, postoperative pain and analgesic consumption in video-assisted thoracic surgery.

ultrasound-guided nerve block is an important part of multi-mode analgesia to decrease the consumption of opioids. thoracic paravertebral block is considered as an ideal regional analgesic choice for video-assisted thoracic surgery, but it still has some side effects, such as pneumothorax, vascular injury, especially for novices. recent years, ultrasound-guided mid-point transverse process to pleura block and erector spinae plane block are reported for thoracic surgery. the insertion depth in these two methods is more superficial than traditional paravertebral block. they could have less side effects. therefore, we design a randomised control study to compare them on block effects, postoperative pain and analgesic consumption in video-assisted thoracic surgery.

Eligibility criteria:
inclusion criteria: * selective lobetomy under vats * asa classfication 1-3 exclusion criteria: * history of thoracic surgery * double lateral vats * allergy to local anesthetics * coagulation disorders * severe heart diseases, hepatic or renal insufficiency * a history of chronic pain or chronic opioid use * psychiatric disease or uncooperative * bmi\>28 kg/m2 * vats transfered to open thoractomy

Keywords: ultrasound-guided nerve block postoperative pain
evaluate the distribution and dynamic behavior of nuclide labeled th-sc01 cells in vivo in patients with radiation proctitis

Conditions: Radiation Proctitis

Summary: a phase l clinical study evaluating the distribution and dynamic behavior of nuclide labeled th-sc01 cells in vivo in patients with radiation proctitis


Eligibility criteria:
inclusion criteria: 1. signed informed consent 2. good physical condition (who performance status score 0-1). 3. patient received radiotherapy after being pathologically diagnosed with pelvic malignant tumors 4. patient diagnosed with chronic radiation proctitis after undergoing colonoscopy more than 6 months after the completion of radiotherapy and did not respond to conventional treatment. 5. the lent-soma score was ≥1 during the screening period. 6. all subjects and their partners were not planning to have a child from screening to the end of the trial and agreed to use effective non-drug contraception during the trial. exclusion criteria: 1. patients with severe, progressive and uncontrollable diseases of the liver, blood, gastrointestinal tract, endocrine system, lungs, heart, nervous system, mental system or brain. 2. patients with allergic constitution or severe systemic autoimmune diseases. 3. patients with active massive gastrointestinal bleeding or acute intestinal obstruction during the screening period. 4. pregnant or lactating women. 5. patients with rectal stenosis or fistula formation that restricts endoscopic treatment and require surgical treatment. 6. patients with a lent-soma score of 4 during the screening period. 7. serum virology test (hbeag, hcv antibody, hlv antibody, treponema pallidum antibody) positive. 8. patients with uncontrolled tumors, tumor recurrence or metastasis. 9. subjects received any investigational drug within 3 months prior to the screening. 10. subjects received stem cell treatment. 11. participants considered inappropriate to participate in this clinical trial
modelling in the quantitative analysis of brain pet scans in patients with alzheimer's disease

Conditions: Patients With Alzheimer's Disease

Summary: pet/ct scans with 18f-fdg can be carried out for the detection of neurodegenerative diseases with hypometabolisms characteristic of the pathologies sought. the diagnosis is given by the clinician after a visual analysis of the data. to complete the diagnosis, a semi-quantitative analysis of the images is recommended (european recommendations) in addition to the visual analysis.

pet/ct scans with 18f-fdg can be carried out for the detection of neurodegenerative diseases with hypometabolisms characteristic of the pathologies sought. the diagnosis is given by the clinician after a visual analysis of the data. to complete the diagnosis, a semi-quantitative analysis of the images is recommended (european recommendations) in addition to the visual analysis. pet technology is improving from year to year thanks to the arrival of a new pet technology called digital. in addition, correction methods have been developed to improve pet images and thus improve the detection of different pathologies in pet. the psf (point spread function) tool enables partial volume effects to be corrected. the psf consists of correcting the impulse response of the system, and allows a visual improvement of the images. currently not recommended in brain pet/ct reconstructions, it remains to be evaluated for the quantitative analysis of acquisitions.

Eligibility criteria:
inclusion criteria: * brain pet/ct scans at 18f-fdg of patients with alzheimer's disease carried out in the nuclear medicine department of the nancy-brabois university hospital since december 2017 on digital pet devices. exclusion criteria: * patients who have expressed their opposition to the use of their data (poster in the service).

Keywords: alzheimer disease psf modelisation quantitative analyze
a study of the efficacy and safety of voriconazole for the treatment of fungal infections

Conditions: Candidiasis; Cryptococcosis; Aspergillosis

Summary: the purpose of this study is to evaluate the efficacy and safety of vfend for the treatment of fungal infections


Eligibility criteria:
inclusion criteria: * systemic or invasive fungal infection * infection caused by organism for which there is no current treatment or infection with evidence of failure and/or intolerance to treatment with approved antifungal agents exclusion criteria: * liver function test abnormalities * renal disease * fungal infections not considered to be invasive or systemic
multidisciplinary bladder-preservation therapy for bladder cancer

Conditions: Bladder Cancer

Summary: a multidisciplinary approach has led to the development of bladder-preservation therapy using maximal transurethral resection followed by radiotherapy with concomitant radio-sensitizing chemotherapy for muscle-invasive bladder cancer.

multidisciplinary management improves complex treatment decision making in cancer care, but its impact for bladder cancer has not been documented. although radical cystectomy (rc) has long been the standard of care for the management of muscle-invasive bladder cancer (mibc), a multidisciplinary approach has led to the development of bladder-preservation therapy using maximal transurethral resection (turbt) followed by radiotherapy with concomitant radio-sensitizing chemotherapy for mibc. there are no randomized-controlled data comparing radical cystectomy with multidisciplinary bladder-preservation therapy (mbpt) available for comparison. however, observational data continues to support the use of mbpt as an acceptable alternative for patients with mibc who wish to preserve their bladder or are not candidates for cystectomy because it may result in equivalent disease outcomes in select patients and offers the benefit of maintaining a functioning urinary system with subsequent improvements in quality of life. but there are also lots of issues need to be studied, such as the patient selection, approaches for completeness of turbt, choices of radio-sensitizing chemotherapy, accuracy of radiotherapy and so on. in this study, the investigators plan to prospectively recruit 80 mibc patients, who don't want to receive rc or are not candidates for rc, treated with mbpt from nov 2018 to dec 2020 in peking university third hospital. the investigators will collect, compare and analyze their clinic-pathological data before and after mbpt, in order to confirm the safety and efficacy of mbpt for mibc in china. at the same time, the investigators want to find out the patients who are not suitable for mbpt and the approach which can improve the efficacy of mbpt, as a result, the investigators intend to make a standard mbpt approach for chinese mibc patients.

Eligibility criteria:
inclusion criteria: 1. bladder urothelial carcinoma 2. clinical stage: t2-t4, non-metastasis 3. eastern cooperative oncology group score (ecog)≤ 1, karnofsky performance score≥ 70 4. patients don't want to receive rc or are not candidates for rc 5. normal bladder function exclusion criteria: 1. history of abdominal and pelvic radiotherapy 2. history of other malignant tumor 3. pregnant or lactating patients 4. severe comorbidity: cardiac infarction, arrhythmia, heart failure, et al

Keywords: multidisciplinary; bladder cancer; bladder-preservation
fibre and mental wellbeing feasibility trial

Conditions: Affect (Mental Function); Sleep; Anxiety; Stress

Summary: this feasibility study will explore whether adding an extra 10 grams of fibre to participants' daily diet for two weeks would improve their mental health and wellbeing.

the current pre-post single-arm feasibility trial will investigate whether increasing daily fibre intake by 10 grams for two weeks enhance depression, anxiety, stress, sleep quality, gut health, and optimism in 18-40 year-old young adults. participants will be provided a list of high fibre food items. outcome measures will be acquired before and after 2-weeks . these will include cognitive measures of measures of depression, anxiety, and stress symptomatology; sleep; gastrointestinal symptomatology; optimism.

Eligibility criteria:
inclusion criteria: * aging between 18-40 years old * having normal vision and hearing * having a body mass index between 18.5 and 30 * not following a high fibre diet \>20g fibre/day as assessed by using the fiberscreen exclusion criteria: * smoking * having food allergies * following restrictive and/or unbalanced diets * changing dietary intake majorly in past month * being diagnosed with any psychiatric or neurologic conditions * being diagnosed with any cardiometabolic diseases, or hypertension or thrombosis related disorders or suffer from thyroid disease * currently taking anticoagulants, antiplatelet medication, antidepressants, proton-pump inhibitors * currently consuming prebiotic or probiotic supplements or laxatives * continuous antibiotic use for \> 3 days within 1 month prior to enrolment * continuous use of weight-loss drug for \> 1 month before screening * having a significant gastrointestinal (gi) condition

Keywords: fibre depression anxiety stress optimism sleep gut health
use of platelet-rich plasma (prp) therapy in patients with brittle nail syndrome

Conditions: Nail Diseases

Summary: the purpose of this study is to assess the efficacy and safety of platelet-rich plasma therapy for brittle nail syndrome


Eligibility criteria:
inclusion criteria: * patients who have been diagnosed with brittle nails * must understand and voluntarily sign an informed consent form * must be male or female and aged 18-95 years at time of consent * must be able to adhere to the study visit schedule and other protocol requirements * a nail clipping with histopathology that is negative for the presence of dermatophyte infection * patient must present with at least a score of 2 on the pga scale. exclusion criteria: * inability of the patient to provide written informed consent for any reason. * subject has psoriasis, lichen planus, dermatophyte infection or other confounding abnormalities that are severe enough to result in a clinically abnormal fingernail * use of any medication within 90 days prior to start of study * inability to abstain for nail polishes, nail gels during the study period * subject is pregnant or planning pregnancy.

Keywords: nails brittle nail syndrome platelet-rich plasma